CytomX Therapeutics CTMX Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$17.37M-154% | $31.87M— | —— | -$99.32M+14.3% | ||
| $6.3M-17.8% | $7.67M-10.4% | $8.56M-19.5% | $10.63M-19.3% | ||
| —— | —— | —— | $35.2M+440,050% | ||
| $221K— | —— | —— | —— | ||
| —— | —— | —— | $3.18M— | ||
| -$66.15M+44.1% | -$118.25M-32.9% | -$89.01M-637% | $16.57M+149% | ||
| $146K0.0% | $146K0.0% | $146K0.0% | $146K0.0% | ||
| -$75.59M+12.3% | -$86.23M-53.9% | -$56.04M+49.4% | -$110.79M+6.9% | ||
| —— | $310K-63.1% | $840K-51.7% | $1.74M+8.1% | ||
| $192.52M+23.8% | $155.49M-63.4% | $424.83M— | $0-100% | ||
| $133M-47.9% | $255.5M-7.1% | $275M+175% | $100M-19.4% | ||
| -$60.18M-160% | $99.7M— | —— | $98.26M— | ||
| $109.66M+1,487% | $6.91M+1,132% | $561K— | $0— | ||
| $110.45M+1,368% | $7.52M-75.1% | $30.23M+4,565% | $648K-99.4% | ||
| -$24.89M— | —— | -$177.66M— | —— | ||
| $2.21M-58.5% | $5.31M-28.4% | $7.42M+14,167% | $52K+118% | ||
| $146K0.0% | $146K0.0% | $146K0.0% | $146K0.0% | ||
| $1.23M-24.2% | $1.62M-20.1% | $2.03M-11.7% | $2.3M-10.3% | ||
| -$402K-279% | -$106K— | $0+100% | -$254K— | ||
| —— | —— | —— | -$9.78M— | ||
| —— | —— | —— | $3.18M— | ||
| -$4.48M-9.8% | -$4.08M-9.5% | -$3.73M-9.3% | -$3.41M-8.9% | ||
| $192.52M+23.8% | $155.49M-63.4% | $424.83M— | $0-100% | ||
| $133M-47.9% | $255.5M-7.1% | $275M— | —— | ||
| $811K+32.3% | $613K+9.3% | $561K-13.4% | $648K-74.1% | ||
| —— | —— | —— | —— | ||
| -$66.15M+44.1% | -$118.25M-32.9% | -$89.01M-637% | $16.57M+149% | ||
| $3M— | $0— | —— | —— | ||
| —— | —— | $29.67M— | —— | ||
| -$75.81M+12.4% | -$86.54M-52.2% | -$56.88M+49.5% | -$112.53M+6.7% | ||
| -$75.81M+12.4% | -$86.54M-52.2% | -$56.88M+49.5% | -$112.53M+6.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does CytomX Therapeutics generate?
- CytomX Therapeutics (CTMX) generated -$80.1M in operating cash flow over the trailing twelve months.
- What is CytomX Therapeutics's free cash flow?
- After $347.0K of capital expenditures, CytomX Therapeutics's free cash flow was -$80.2M over the trailing twelve months, up 1.7% year over year.
- Where does CytomX Therapeutics's cash flow data come from?
- Every line is extracted from CytomX Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
